Innervace is a regenerative therapy company developing technology that acts as pre-formed, anatomically-inspired, implantable tissue pathways to directly replace lost connections due to brain degeneration or injury. Their lead program mimics the lost nigrostriatal pathway in patients with Parkinson's disease (PD).
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 09/08/22 | $40,000,000 | Series A |
BioAdvance Deerfield Management Company, L.P.  IP Group Penn Medicine WARF Ventures | undisclosed |
